Aurobindo Pharma Limited published newspaper advertisements of its unaudited financial results for the third quarter and nine months period ended December 31, 2025, in Business Standard and Nava Telangana on February 11, 2026. The pharmaceutical company formally communicated this publication through official letters to both the National Stock Exchange of India Limited and BSE Limited.

Newspaper Publication Details

The company fulfilled its regulatory obligations by publishing the Q3FY26 financial results in leading newspapers. Company Secretary B. Adi Reddy signed the communication letters sent to stock exchanges, confirming the newspaper advertisement publication.

Strong Q3FY26 Consolidated Financial Performance

The published results highlight robust consolidated financial performance with total income from operations reaching ₹86,459.0 million, representing significant year-over-year growth. Net profit after tax stood at ₹9,098.0 million, while total comprehensive income for the period reached ₹11,375.3 million.

Standalone Results Performance

The standalone financial results showed total income from operations of ₹27,472.8 million for Q3FY26, while net profit after tax reached ₹5,820.7 million. The standalone earnings per share stood at ₹10.02 for the quarter.

Nine Months Performance Highlights

For the nine months period ended December 31, 2025, consolidated total income reached ₹2,47,997.4 million with net profit of ₹25,821.3 million. The comprehensive income for the nine months period totaled ₹37,567.7 million, demonstrating sustained business growth across multiple quarters.

Aurobindo pharma Limited has announced its earnings call schedule to discuss the third quarter financial results for FY26. The pharmaceutical company informed stock exchanges about the upcoming investor interaction as part of its regulatory disclosure requirements.

Earnings Call Details

The company has scheduled the earnings call with specific timing and access arrangements for analysts and investors.

Regulatory Compliance

The announcement was made pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary B. Adi Reddy signed the communication digitally on February 2, 2026, ensuring compliance with regulatory disclosure norms.

The notification was simultaneously sent to both major stock exchanges where the company is listed:

• National Stock Exchange of India Limited (Company Code: AUROPHARMA)
• BSE Limited (Company Code: 524804)

Access and Participation

Investors and analysts interested in participating in the earnings call need to pre-register through the provided Zoom link. The company has indicated that the earnings presentation will be made available on its official website following the results announcement.

The call will focus on discussing the unaudited financial results for the third quarter and nine months period ended December 31, 2025, providing stakeholders with insights into the company's operational and financial performance during this period.

Company Information

Aurobindo Pharma Limited operates with its corporate office located at Galaxy, Floors 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad. The company maintains its commitment to regulatory transparency through timely disclosure of material information to investors and market participants.